Compass Therapeutics, Inc. (NASDAQ:CMPX) Sees Significant Increase in Short Interest

Compass Therapeutics, Inc. (NASDAQ:CMPX) saw a large growth in short interest in February. As of February 15th, there was short interest totalling 3,530,000 shares, a growth of 28.4% from the January 31st total of 2,750,000 shares. Approximately 4.4% of the company’s stock are sold short. Based on an average trading volume of 1,330,000 shares, the short-interest ratio is currently 2.7 days.

Wall Street Analyst Weigh In

Several research analysts have commented on CMPX shares. Jefferies Financial Group lifted their price target on Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, February 10th. Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their target price for the company from $5.00 to $4.00 in a report on Friday, November 15th. D. Boral Capital reiterated a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research note on Tuesday, February 25th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Finally, Leerink Partnrs downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $11.38.

Compass Therapeutics Trading Down 5.2 %

Shares of CMPX stock traded down $0.15 during mid-day trading on Thursday, reaching $2.63. The stock had a trading volume of 166,092 shares, compared to its average volume of 643,341. The company has a market cap of $361.17 million, a P/E ratio of -7.15 and a beta of 1.17. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $4.08. The business has a 50-day simple moving average of $2.66 and a 200 day simple moving average of $1.98.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Research analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current year.

Hedge Funds Weigh In On Compass Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Rovin Capital UT ADV purchased a new stake in shares of Compass Therapeutics during the third quarter worth about $25,000. Tower Research Capital LLC TRC grew its position in shares of Compass Therapeutics by 298.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock worth $25,000 after buying an additional 12,917 shares in the last quarter. Independent Advisor Alliance bought a new stake in shares of Compass Therapeutics in the fourth quarter worth $26,000. BNP Paribas Financial Markets acquired a new stake in Compass Therapeutics in the fourth quarter valued at $27,000. Finally, Intech Investment Management LLC bought a new position in Compass Therapeutics during the 3rd quarter valued at $30,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.